1. Generics Bulletin
  2. >>Business

Supply Chain Constraints ‘Will Limit Vascepa Threat’

Dr Reddy’s And Hikma Have Path To Market

 
• By Dean Rudge

Supply is the million-dollar question for Vascepa ANDA sponsors, with Dr Reddy’s and Hikma receiving a further green light to introduce their generics into the US market.

Drugs question mark
Will Reddy's, Hikma or other ANDA sponsors struggle with icosapent ethyl supply? • Source: Shutterstock

Generic Vascepa (icosapent ethyl) players in the US will “not have access to sufficient quantities of active pharmaceutical ingredient to mount an imposing near-term threat,” meaning the branded purified fish oil product “will retain the lion’s share of icosapent ethyl sales well into 2022 and likely beyond,” an investment bank has forecasted.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.